DIRECTOR CLINICAL PHARMACOLOGY

Location: Copenhagen, Denmark

Position Overview

As part of progressing our lead molecule for treatment of atrial fibrillation, AP31969, we are expanding our clinical pharmacology activities and plan a number of clinical studies to understand various DMPK (Drug Metabolism and Pharmacokinetics) aspects. We therefore establish a new position where you will be responsible for all our clinical pharmacology activities. In addition, you will contribute to the planning and conduct of phase 2 and 3 clinical trials that are being led by our Director of Clinical Operation.

You will be part of a small, very experienced team where we collaborate on all major activities, and across disciplines. This position is an opportunity for a science driven person who thrives in a smaller, hands-on environment where everyone's contribution is acknowledged and considered key for our success.

Key Responsibilities

- Design and implement clinical pharmacology strategy for a small molecule programme.
- Plan, oversee, and interpret Phase 1, ADME, pharmacokinetic (PK), pharmacodynamic (PD), and drug-drug interaction (DDI) studies
- Drive protocol development, clinical study report drafting, and regulatory submissions.
- Work collaboratively with cross-functional teams, including clinical operations, regulatory and non-clinical development
- Manage major and minor tasks independently, from high-level planning to hands-on implementation

Qualifications

- PhD, PharmD, MD, or equivalent in pharmacology, pharmacy, medicine, or related field
- Proven experience in clinical pharmacology
- Demonstrated ability to manage multiple responsibilities with minimal supervision
- Ability to work effectively in a fast-paced, collaborative, and deliver within your timeline and budget
- Advantage: Experience with small molecule drug development
- Advantage: Experience with Phase 2 and Phase 3 clinical trials

Personal Profile

- Hands-on person and motivated to drive and manage clinical pharmacology activities on a day-to-day basis including willingness to work on specific deliverables, e.g. writing up regulatory documents
- Interest in engaging in both strategic and operational activities, including performing major and minor tasks
- Strategic thinker with a deep understanding of the field, the underlying opportunities, constrains and risks
- Always a step ahead in the execution of near-term plans and overall strategy
- Focused on details and delivering quality
- Fluent in English, written and oral
- Good communication and relationship-building skills

- Preferably based in the Copenhagen area but not a requirement

What We Offer

- An opportunity to make a significant impact in a small, innovative team
- An informal and flat organisation with a motivating work environment
- Flexible working arrangements – we expect you to be in the office (located at Symbion Frederiksberg) 2-3 days a week
- Competitive salary and warrants (ownership share) in the company

About Acesion Pharma

Acesion Pharma is a Danish clinical stage biotech developing first-in-class therapies for atrial fibrillation (AF). Acesion has successfully pioneered and developed SK channel inhibitors from discovery stage to clinical proof-of-concept. Our current goal is to further progress clinical development of the oral lead candidate AP31969 and to unfold the potential to become a first-line treatment in this large cardiovascular indication. AF is the most common type of cardiac arrhythmia and forecast to affect 25 million people in the US and EU by 2030. It is characterised by an irregular and high heart rate and is associated with impaired quality of life, increased rate of hospitalisation, and a five-fold increased risk of stroke. Existing drug therapies are associated with risk of serious cardiac or other adverse effects, resulting in a great need for safer drugs. There has been a lack of innovation and development with no new chronic AF drug approved for nearly two decades. Our lead molecule currently in phase 2, AP31969 has potential to become a transformative novel treatment for AF patients and in the Acesion team we are excited and driven to fulfill this goal with a molecule arising from our own discovery efforts.

Acesion Pharma is a privately owned company based in Copenhagen and backed by Novo Holdings, Canaan, Alpha Wave Ventures, Global BioAccess Fund, Wellcome Trust, Broadview Ventures and FC Capital.

Application Process

Please introduce yourself and your motivation to apply together with a resume detailing qualifications and experience by email to CEO Anders Gaarsdal Holst (agh@acesionpharma.com), who you are also welcome to contact to set up a call.

Applications will be reviewed on a rolling basis.

Deadline 31. October 2025.